BioMarin Pharmaceutical Inc. (BMRN) News
Track canonical SquawkNews coverage tagged to BMRN, BioMarin Pharmaceutical Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 28 indexed stories across 14 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
BioMarin halts studies for Voxzogo in Noonan syndrome
Shares of BioMarin Pharmaceutical NASDAQ:BMRN slipped in premarket trading on Tuesday after the company announced plans to discontinue the development of its dwarfism therapy Voxzogo for Noonan syndrome, a rare genetical
EQUITY | Sep 15, 2026, 01:11 PM UTC
L
BioMarin discontinues VOXZOGO development for Noonan syndrome in children
BioMarin announced it will discontinue development of VOXZOGO for children with Noonan syndrome.Key Highlights:Original SEC Filing: BIOMARIN PHARMACEUTICAL INC [ BMRN ] - 8-K - Sep. 15, 2026This is an AI-powered summary.
REGULATION | Sep 15, 2026, 12:33 PM UTC
L
BMRN: Portfolio expansion, Amicus deal, and VOXZOGO growth drive strong outlook and pipeline innovation
The conference highlighted robust portfolio expansion, including the Amicus acquisition, which adds two high-growth assets and is expected to drive significant revenue and EPS accretion. VOXZOGO continues strong global g
EARNINGS | Sep 10, 2026, 03:09 PM UTC
L
HC Wainwright maintains BioMarin’s $60.00 price target
EQUITY | Sep 10, 2026, 10:46 AM UTC
L
BMRN: Strong growth, pipeline expansion, and global market execution drive future momentum
Metabolic and skeletal franchises are driving robust growth, with VOXZOGO expanding globally and new pipeline assets advancing in hypochondroplasia, DMD, HPP, and FSGS. Strategic deals, a strong commercialization platfor
EQUITY | Sep 09, 2026, 09:02 PM UTC
L
BMRN: Robust growth, pipeline expansion, and global execution position the business for sustained success
Metabolic and skeletal franchises are driving strong revenue growth, with VOXZOGO and Amicus products expanding globally. R&D pipeline advances include promising hypochondroplasia data, new deals, and upcoming readouts f
EQUITY | Sep 09, 2026, 08:02 PM UTC
L
Ten healthcare stocks with A-rated valuations and strong revenue growth
Healthcare stocks remain a focal point for investors as pharmaceutical innovation, biotechnology advancements, and managed care expansion continue to drive growth across the sector.While many healthcare companies trade a
EQUITY | Sep 09, 2026, 03:01 PM UTC
M
BioMarin announces positive Phase 3 VOXZOGO results in NEJM
BioMarin said its Phase 3 VOXZOGO (vosoritide) study in hypochondroplasia has positive results, published as NEJM evidence.
EQUITY | Sep 09, 2026, 01:07 PM UTC
L
BioMarin EVP, Chief Legal Officer sells $1,163,748 in shares
BioMarin officer Davis George Eric, EVP and Chief Legal Officer, sold 17,557 common shares on 2026-09-02 for $1,163,748. Weighted average price was $66.284; executed prices ranged from $66.271 to $66.39.
EQUITY | Sep 03, 2026, 11:20 PM UTC
L
BMRN - BioMarin to Participate in Upcoming Investor Conferences
BMRN - BioMarin to Participate in Upcoming Investor Conferences
EQUITY | Sep 02, 2026, 01:01 PM UTC
L
BioMarin management to present at September investor conferences
BioMarin Pharmaceutical management will present at upcoming investor conferences in September. An audio webcast of the presentations will be available live.
EQUITY | Sep 02, 2026, 01:01 PM UTC
L
Piper Sandler keeps BioMarin at Overweight, lifts price target
Piper Sandler maintains BioMarin Pharmaceutical at Overweight and raises its price target to $90.00 per share from $88.00.
EQUITY | Sep 01, 2026, 05:29 PM UTC
L
BioMarin completes acquisition of Alesta subsidiary
BioMarin completed the acquisition of Alesta, which became a wholly owned subsidiary after the August 31, 2026 closing.
MNA | Sep 01, 2026, 01:34 PM UTC
L
BioMarin closes Alesta Therapeutics acquisition
BioMarin (BMRN) announced the close of its acquisition of Alesta Therapeutics.
MNA | Sep 01, 2026, 01:05 PM UTC
L
BioMarin Pharmaceutical maintained at Buy by Jefferies
Jefferies maintained its Buy rating on BioMarin Pharmaceutical.
EQUITY | Aug 31, 2026, 05:43 PM UTC
L
ASND, BMRN Stocks Rise: Street Calls Patent Peace A Clean Overhang Lift, Keep Ratings Unchanged
ASND, BMRN Stocks Rise: Street Calls Patent Peace A Clean Overhang Lift, Keep Ratings Unchanged
EQUITY | Aug 31, 2026, 05:30 PM UTC
L
Crude oil gains over 2%; Dallas Fed index surges in August
The Dallas Fed's general business activity index for Texas manufacturing rose to 11.6 in August from 1.3 in July, its strongest reading since January 2025.
CENTRAL_BANK | Aug 31, 2026, 04:46 PM UTC
L
BioMarin price target raised to $60 by HC Wainwright
HC Wainwright & Co. raised its BioMarin Pharmaceutical price target to $60.00/share from $59.00.
EQUITY | Aug 31, 2026, 04:08 PM UTC
M
BioMarin announces global settlement with Ascendis over Yuviwel royalties
BioMarin says Ascendis will pay royalties to BioMarin on Yuviwel sales in the U.S., EU, Brazil and South Korea under a global settlement.
EQUITY | Aug 31, 2026, 06:00 AM UTC
L
BMO, Wedbush, Wolfe and RBC issue stock initiations
BMO, Wedbush, Wolfe, RBC and Cantor initiate coverage with ratings changes on AKTS, ALNY, ASND, BCAX, BMRN, CATX, PRME, AFL, AGMB, COR and MCK.
EQUITY | Aug 19, 2026, 11:09 AM UTC
L
BioMarin agrees to buy Alesta Therapeutics for ALE1 asset
BioMarin Pharmaceutical agreed to purchase Alesta Therapeutics, including the clinical-stage asset ALE1, for $275 million upfront plus up to $215 million in milestone payments and expects revised full-year 2026 guidance
EARNINGS | Aug 18, 2026, 05:37 PM UTC
H
BioMarin to Acquire Alesta Therapeutics for Hypophosphatasia Program
BioMarin (BMRN) announces an acquisition of Alesta Therapeutics to gain ALE1, described as a potential first oral therapy for hypophosphatasia, adding a clinical program to its pipeline.
MNA | Aug 18, 2026, 12:31 PM UTC
L
BioMarin Pharmaceutical Raises FY2026 Adj EPS Guidance from $4.85-$5.05 to $4.90-$5.10 vs $3.64 Est; Raises FY2026 Sales Guidance from $3.82
BioMarin Pharmaceutical (NASDAQ: BMRN ) raises FY2026 Adj EPS guidance from $4.85-$5.05 to $4.90-$5.10 vs $3.64 analyst estimate. Raises FY2026 sales outlook from $3.825 billion-$3.925 billion to $3.875 billion-$3.925 bi
EARNINGS | Aug 06, 2026, 08:14 PM UTC
L
BMRN BMRN - BioMarin to Host Second Quarter 2026 Financial Results Conference Call and Webcast on Thursday, August 6, 2026, at 4:30pm ET - C
BMRN BMRN - BioMarin to Host Second Quarter 2026 Financial Results Conference Call and Webcast on Thursday, August 6, 2026, at 4:30pm ET
EARNINGS | Jul 30, 2026, 01:01 PM UTC
L
BMRN Biomarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified
BMRN Biomarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU Syndrome ReNU syndrome was discovered in 2024 and there are no Medicines ap
EQUITY | Jul 27, 2026, 01:06 PM UTC
L
BioMarin Says FDA Accepts Filing for Voxzogo's Full Approval in Children With Achondroplasia
() -- BioMarin Pharmaceutical (BMRN) said Monday that the US Food and Drug Administration has accepted its supplemental new drug application seeking full approval of Voxzogo to treat children with achondroplasia. The reg
REGULATION | Jul 13, 2026, 01:37 PM UTC
L
BioMarin announces FDA accepts sNDA for full approval of Voxzogo
BioMarin Pharmaceutical...
REGULATION | Jul 13, 2026, 01:08 PM UTC
H
BioMarin price target lowered to $62 from $66 at RBC Capital
RBC Capital analyst Luca Issi lowered the firm's price target on BioMarin to $62 from $66 and keeps a Sector Perform rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The biotech
RATES | Jul 07, 2026, 11:28 AM UTC